YOST LAW BLOG

Risks and Injuries from Clonazepam Overdose from FDA Recall

Know Your Rights About Filing a Clonazepam Lawsuit

In November 2024, thousands of patients and families across the United States were shocked to learn about a significant recall involving a widely prescribed anxiety medication: Clonazepam, also known by its brand name, Klonopin. Individuals across the country are filing clonazepam lawsuits. The recall, announced by Endo, Inc.—the drug manufacturer of the orally disintegrating Clonazepam...

CONTINUE READING
Taking Mislabeled Clonazepam Medication

Are You Affected by the Clonazepam Recall?

The FDA Food and Drug Administration has issued a recall for 16 lots of Clonazepam manufactured by Endo, Inc., following a critical labeling error. The product safety recall is hoping to prevent medication errors. According to the safety alert, the strength listed on the product cartons (0.125 mg) did not match the actual strength of...

CONTINUE READING
Missouri Woman Awarded $20 Million in Missouri Metal-on-Metal Hip Case

Missouri Woman Awarded $20 Million in Missouri Metal-on-Metal Hip Case

Mary Bayes and her husband Philip Bayes received their holiday presents early this year. A St. Louis federal jury awarded the couple $20 million and $1 million respectively for the injuries Mrs. Bayes suffered as a result of her defective Biomet M2a Magnum metal-on-metal hip replacement. Although the second trial, which ended recently, resulted in...

CONTINUE READING
disabuse checking

The Truth Behind Dangerous Medical Devices

Recently, attorney Tom Yost sat down with Elsa, from WMAR’s Midday Maryland to discuss the potential dangers of medical devices, specifically Essure birth control and metal on metal hip implants. He talks about the way in which the FDA approves these devices and allows them to be sold. As well as what the next steps...

CONTINUE READING
defective drug law firm baltimore, medication error attorneys maryland, drug label warnings, heart attack & stroke lawyers

New Warning Labels for Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

In the wake of new research indicating increased risks of heart attacks and strokes, the FDA is requiring new warning labels for nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, which for years have been viewed largely as reliable, over-the-counter solutions to a myriad of common health problems. On July 9th, 2015, the Food and Drug...

CONTINUE READING
defective medical device lawyers baltimore, stryker hip recall, product liability attorneys, personal injury law firm maryland

Defective Medical Devices Can Have Devastating Consequences

Manufacturers of medical devices have an obligation to ensure the safety of their products. The effects of a faulty device can be devastating.  Companies that fail in their duty to keep patients safe must be held fully accountable. If you received a hip replacement from the Stryker Orthopedics Corporation, you could be entitled to compensation....

CONTINUE READING

FDA’s Generic Drug Warning Labeling Rule Change

The New York Times recently published an editorial in support of the FDA’s generic drug labeling rule. AAJ (American Association for Justice) released an editorial board memo on generics and Katie Gommel (AAJ Press Secretary) did an outstanding job working behind the scenes with Public Citizen to shape this editorial. Late last year, the Food...

CONTINUE READING

FDA to Review Rules for Over-the-Counter Drugs

The FDA has launched a review of the way it determines the safety of over-the-counter drugs such as acetaminophen. Current regulations allow the manufacturers of over-the-counter medications to drag their feet when it comes to updating warning labels. The process of increasing the warning on a potentially dangerous drug can take years, during which time hundreds,...

CONTINUE READING

Generic Drug Manufacturers Oppose FDA Label Proposal

The FDA has proposed label changes that would require generic drug manufacturers to update warning labels when new safety concerns come to light, even if those label changes have not first been made by the original manufacturer of the medication. The Generic Pharmaceutical Association, a trade group representing generic drug manufacturers, claims the proposed changes...

CONTINUE READING